Development and Validation of a Reversed-Phase HPLC Method for the Simultaneous Determination of Telmisartan and Its Related Compound B (Positional Isomers) in the Bulk Drug
Abstract
Full Text:
PDFReferences
Drugs.com: Telmisatan.
Pritor prescribing information.
Sharpe M., Jarvis B., Goa K.L. Telmisartan: a review of its use in
hypertension, Drugs. 2001; 61(10): 1501–29p.
Sanchis-Gomar F., Lippi G. Telmisartan as metabilic modulator: a new perspective in sports doping, J Strength Condit Res. 2011; 1.
Cytoplasmic and Nuclear Receptors: Advances in Research and Application. 2011 Edn. Scholarly Edns, 2012, 21p. Retrieved 2 April 2013.
Feng X., Luo Z., Ma L., et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway, J Cell Mol Med. 2011; 15(7): 1572–81p.
He H., Yang D., Ma L., et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-dependent pathways, Hypertension. 2010; 55(4): 869–79p.
Li L., Luo Z., Yu H., et al. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-activation, Diabetes. 2012; 62(3): 762–74.
Drug.com:Micardis.
Chemical Book; HTTP://www.chemicalbook.com/ProductChemicalPropertiesCB325676.
International Conferences on Harmonization of Technical Requirements for the Registration of pharmaceutical for human use(ICH), Guideline Q2 (R)-validation of Analytical procedures; Text and Methodology (last reviewed at 3/1/2011) www.emea.europa.eu/htms/human/ich/ichquality.htm.
Bliesner D.M. Validating Chromatographic Method: A Practical Guide. New Jersey, USA: Wiley; 2007, 97–130p.
Kazakevich Y., Lobrutto R. HPLC for Pharmaceutical Scientists. New Jersey, USA: Wiley and Sons Inc.; 2007, 455–91p.
Refbacks
- There are currently no refbacks.